Medicine
Pharmacokinetics of Drug Metabolism in Hepatic Impairment
Quick fact
In severe cirrhosis, plasma drug levels can rise by several-fold, and even modest doses of opioids or benzodiazepines can cause life-threatening respiratory depression.
Why this is interesting
We all know the liver processes drugs, but when it's diseased, even a standard dose of a familiar medication can become toxic—or fail to work. Why does liver impairment turn routine prescribing into a high-stakes balancing act?
Read the full explanation
Understanding Pharmacokinetics of Drug Metabolism in Hepatic Impairment
Imagine a factory (the liver) that metabolizes drugs, turning them into water-soluble forms that can be excreted. In a healthy liver, enzymes (notably the cytochrome P450 family) efficiently process drugs as they pass through. When the liver is impaired—due to cirrhosis, hepatitis, or other conditions—the factory's machinery slows down or loses capacity. This means drugs are broken down more slowly, so they stay in the body longer and reach higher concentrations. Additionally, blood flow to the liver may be shunted away from hepatocytes, and protein binding may change, further complicating the picture. The net result is that standard doses can become overdose, while prodrugs (which need activation by the liver) may be ineffective.
A deeper explanation
The liver's ability to metabolize drugs depends on three key factors: hepatic blood flow, intrinsic enzyme activity (capacity), and plasma protein binding. In hepatic impairment, these can all be altered. Chronic liver disease reduces functional liver mass and enzyme expression, especially for CYP450 isoforms like CYP3A4 and CYP2D6. Portal hypertension can create shunts that bypass the liver, reducing the first-pass effect and increasing bioavailability of orally administered drugs. Meanwhile, decreased synthesis of albumin and other proteins reduces protein binding, so more free (active) drug circulates, enhancing both therapeutic and toxic effects. The Child-Pugh score is a clinical tool used to grade severity and guide dosing adjustments, but pharmacokinetic changes are not uniform across all drugs—some are more affected than others. Because the liver has large functional reserve, changes may be minimal in mild impairment but severe in advanced disease, making individualized assessment crucial.